Evolution of drug-eluting biomedical implants for sustained drug delivery
| Autor: | Sean M. Geary, Juliana C. Quarterman, Aliasger K. Salem |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Drug
Drug Compounding media_common.quotation_subject Pharmaceutical Science 02 engineering and technology History 21st Century 030226 pharmacology & pharmacy Article 03 medical and health sciences 0302 clinical medicine Humans Medicine Drug Approval media_common Drug Implants Therapeutic window United States Food and Drug Administration business.industry Target tissue Drug-Eluting Stents General Medicine History 20th Century 021001 nanoscience & nanotechnology United States Drug concentration Risk analysis (engineering) Delayed-Action Preparations Drug delivery Drug release 0210 nano-technology business Biotechnology |
| Zdroj: | Eur J Pharm Biopharm |
| ISSN: | 0939-6411 |
| DOI: | 10.1016/j.ejpb.2020.12.005 |
| Popis: | In the field of drug delivery, the most commonly used treatments have traditionally been systemically delivered using oral or intravenous administration. The problems associated with this type of delivery is that the drug concentration is controlled by first pass metabolism, and therefore may not always remain within the therapeutic window. Implantable drug delivery systems (IDDSs) are an excellent alternative to traditional delivery because they offer the ability to precisely control the drug release, deliver drugs locally to the target tissue, and avoid the toxic side effects often experienced with systemic administration. Since the creation of the first FDA-approved IDDS in 1990, there has been a surge in research devoted to fabricating and testing novel IDDS formulations. The versatility of these systems is evident when looking at the various biomedical applications that utilize IDDSs. This review provides an overview of the history of IDDSs, with examples of the different types of IDDS formulations, as well as looking at current and future biomedical applications for such systems. Though there are still obstacles that need to be overcome, ever-emerging new technologies are making the manufacturing of IDDSs a rewarding therapeutic endeavor with potential for further improvements. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect